CARDIOL THERAPEUTICS
Commented by Nico Popp on June 15th, 2021 | 13:15 CEST
CureVac, Cardiol Therapeutics, Bayer: Healthcare for the portfolio
Biotechnology and pharmacology offer us great opportunities. For decades, the world has suffered from a few serious diseases: cancer, cardiovascular disease, Alzheimer's, diabetes and others. Where previously only symptoms were treated, there is now the prospect of a cure thanks to new processes. Even if it still takes a little time to reach market maturity: the innovative companies are already on the market, investors can invest.
Read
Commented by André Will-Laudien on June 7th, 2021 | 08:32 CEST
CureVac, Cardiol Therapeutics, Formycon, NanoRepro - Pharma stocks with potential!
In Germany, around 231,000 people died as a result of cancer in 2019. As reported by the Federal Statistical Office, cancer was the cause of a quarter of all deaths. This proportion has hardly changed within 20 years, even though the number of cancer deaths has increased by around 10% since 1999. The precise number 1 cause of widespread disease in Germany is cardiovascular disease, such as heart failure, coronary heart disease and myocardial infarction. With 18.2 million deaths, they represented the most common cause of death worldwide in 2019. In Europe, more than 4 million people die each year due to such a disease, 1.4 million of whom are younger than 75. So research continues to be in demand. We look at interesting representatives of the industry.
Read
Commented by Stefan Feulner on May 10th, 2021 | 09:14 CEST
CureVac, Cardiol, MorphoSys - Huge sensation in the fight against Corona!
The biotechnology sector gained tremendous attention since the start of the Corona pandemic. With vaccine makers such as BioNTech or Moderna, investors have achieved returns beyond 1000% since the end of 2019. Currently, drug research against Sars-CoV-2 is in full swing. More effective and safe drugs along with vaccination and testing strategies are critical to managing the pandemic. For investors, this meant a second chance at the next tenbagger.
Read
Commented by Nico Popp on May 3rd, 2021 | 07:25 CEST
BioNTech, CureVac, Cardiol Therapeutics: In on the next blockbuster from the start
The two German companies BioNTech and CureVac, have been causing quite a stir since the outbreak of the pandemic. At first, the biotech newcomers were known only to hard-nosed investors who are used to seizing long-term opportunities and accepting initial uncertainty to do so. Even during the first months of the pandemic, it was far from clear whether BioNTech and CureVac would be successful. Only a few insiders had the right instinct early on thanks to the necessary background knowledge and are pleased with BioNTech's annual performance of 260%. But what characterizes the success of innovative biotech companies? And where are the next opportunities lurking? We outline some exciting investment stories.
Read
Commented by Carsten Mainitz on April 13th, 2021 | 09:06 CEST
InnoCan Pharma, Cardiol Therapeutics, BevCanna - Watch out: undiscovered cannabis price rockets!
Whether French explorer Jacques Cartier, who first named the region around present-day Quebec "Canada" in 1535, was acting on a hunch, or simply "Frenching" the word "Kanata" from the language of the Saint Lawrence Iroquois, can unfortunately no longer be determined with certainty today. However, what is certain is that today's "Canada" is the current stronghold of medical "cannabis." Thanks to liberal laws, hemp startups are sprouting up worldwide, and even established companies want a piece of the pie. Here are three interesting candidates for the portfolio, with current news and powerful price potential!
Read
Commented by André Will-Laudien on March 29th, 2021 | 08:15 CEST
Cardiol Therapeutics, Bayer, Formycon: These pharma stocks could explode!
According to official statistics, diseases of the cardiovascular system, such as heart failure, coronary heart disease or myocardial infarction, are the No.1 cause of death in Germany. With 18.2 million deaths, they represented the most common cause of death worldwide in 2019. Thus, on a global average, a good 30% of all deaths are attributable to cardiovascular disease. In Europe, more than 4 million people die each year due to such a disease, 1.4 million of whom are younger than 75. But there are many other dangers to our health. Reason enough to take a closer look.
Read
Commented by Stefan Feulner on March 16th, 2021 | 07:16 CET
Bayer, Cardiol Therapeutics, Xiaomi - Biotech: Blockbuster potential here!
Germany is leading the race for a vaccine against the coronavirus With two companies - BioNTech and CureVac. The biotech industry is currently experiencing a growth spurt that will continue over the next few years, if not decades. In Germany alone, EUR 7 billion is invested annually in research and development. The goal is to develop new therapies to prevent, alleviate and cure diseases. The opportunity for disproportionate share price gains by investing in a company at an early stage of research is gigantic.
Read
Commented by Nico Popp on March 10th, 2021 | 09:27 CET
BioNTech, CureVac, Cardiol Therapeutics: Biotech rockets off the launchpad
We all know that health is the greatest good. But it is only the last year or so that we've become fully aware of the fact that everything changes during a pandemic. Work, family, leisure time - no area of life is not currently under the influence of Covid-19. But even if lockdown fatigue is slowly but surely setting in, investors should remain wide awake. In many sectors, the course is currently being set for the future - especially in the pharmaceutical and biotech industries. Reason enough to take a closer look at these three stocks.
Read
Commented by Carsten Mainitz on March 3rd, 2021 | 07:34 CET
Evotec, Cardiol Therapeutics, MorphoSys - Watch out: Great upside potential here in the short term
In the pandemic, investors have learned that small biotech companies, some still with a start-up character, can be worth billions overnight. BioNTech and CureVac are familiar names from the press. Both are linked by the Corona drug and the fact that they are headquartered in Germany. Two other German companies, Evotec and MorphoSys, have written a good growth story on the stock exchange in recent years: small becomes big! Small is also still the Canadian Cardiol Therapeutics. With the announced dual listing on the US technology exchange Nasdaq, a valuation boost could be imminent.
Read
Commented by André Will-Laudien on February 17th, 2021 | 10:39 CET
Cardiol Therapeutics, Formycon, Teva Pharmaceuticals: COVID in focus!
According to recent statistics from the WHO, nowhere is research currently more intense than in the area of viral diseases. At least 248 vaccine projects have been initiated against COVID-19 since January 2020, but only the research projects have already been reported. But of course, we humans do not only fall ill from flu viruses and their dangerous mutants, but the permanent change in our lives alone intensifies diseases that arise from lack of exercise and contact and sometimes cause worse consequences than a flu-like effect. Everyone is currently looking to hopeful vaccine solutions, but several biotech and pharmaceutical companies can still make us healthier with new developments.
Read